Is Oncotype DX testing informative for breast cancers with low ER expression? A retrospective review from a biomarker testing referral center

Purpose: It remains unclear whether patients with HER2-negative, low-estrogen receptor (ER-low)-positive early breast cancer (BC) benefit from Oncotype DX® (ODX) testing. Methods: We conducted a retrospective review of cases referred for ODX testing over a seven-year period from a breast biomarker t...

Celý popis

Podrobná bibliografie

Hlavní autoři:	John Loggie, Penelope J. Barnes, Michael D. Carter, Daniel Rayson, Gillian C. Bethune
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-06-01
Edice:	Breast
Témata:	ER-low Breast cancer Estrogen receptor Oncotype DX Expression intensity Immunohistochemistry
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S0960977624000468
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!